CPIX Cumberland Corp: Enterprise Value to EBITDA Ratio
This EV/EBITDA chart for Cumberland Pharmaceuticals (CPIX) stands at 0.00. The business relies on a flawless delivery system for critical medications to clinics. The model operates by outsourcing production to third-party enterprises, utilizing only its own hubs in the US. Process stability is guaranteed by a fully staffed team of technologists and experts with minimal personnel turnover.
Comprehensive metric breakdowns and analytics for cumberlandpharma.com (CPIX)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Cumberland Pharmaceuticals|CPIX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Cumberland Pharmaceuticals Inc.|CPIX - Company Total Debt|Debt to Book Value Cumberland Corp|CPIX - Company Long-Term Debts|Company Short-Term Debt Cumberland Pharmaceuticals|Quick Ratio cumberlandpharma.com
- financial results and valuation multiples details:
CPIX - Company Net Income|Projected Future Earnings Cumberland Pharmaceuticals|CPIX - Market Cap to Earnings|Future Price to Earnings Cumberland Pharmaceuticals|CPIX - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cumberland Corp|CPIX - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Cumberland Pharmaceuticals|CPIX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months cumberlandpharma.com|CPIX - Earnings per share growth this year|Earnings growth forecast for next year Cumberland Pharmaceuticals
Analysis of all company metrics:Cumberland Pharma (CPIX)
Professional asset selection requires filtering market noise by analyzing business value relative to its operating profit before depreciation and interest. This multiple compares market capitalization with debt and cash holdings, which, combined with the strict financial discipline of Cumberland Pharmaceuticals (CPIX) management, allows for an objective assessment of capital management efficiency in the hospital segment based on the company's current EV/EBITDA trend.
Competitors of Cumberland Pharmaceuticals
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|MNKD - Enterprise Value to EBITDA Ratio|AMPH: Enterprise Value to EBITDA Ratio|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio theravance.com|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SCPH|EV/EBITDA Multiple TECX|TNXP - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|Business Value to Operating Income Before Depreciation EPRX|BHST - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|EXOZ: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ORMP: EV/EBITDA Multiple|Entera Bio (ENTX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MindWalk Holdings|Enterprise Value to Operating Income Before Depreciation ABVC (abvcpharma.com)|EV/EBITDA Multiple QNTM|FibroGen Inc - Enterprise Value to Operating Income Before Depreciation|Telomir Pharma - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RANI|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RLYB|LEXX: EV/EBITDA Multiple|Pulmatrix Inc - Business Value to Operating Income Before Depreciation|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|EV/EBITDA Multiple Aptorum|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|IBO (impactbiomedinc.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|YCBD - Enterprise Value to EBITDA Ratio|PainReform Limited - EV/EBITDA Multiple|CYTO - EV/EBITDA Multiple|LIPO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio optinose.com|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Procaps Group PROC|Enterprise Value to EBITDA Ratio PTPI (Petros)|EV/EBITDA Multiple Qilian International Corp (QLI)|Acelyrin, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TFFP (tffpharma.com)
